Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study
Status:
Completed
Trial end date:
2002-02-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to evaluate the long-term safety and tolerability of 7-day
BTDS in a 28-week open-label extension phase in subjects with chronic nonmalignant pain
syndromes whose pain had been previously controlled by oral opioid combination therapy.